Fibrocell Science (FCSC) Reports Azficel-T Phase 2 in Vocal Cord Scarring Missed Primary Endpoints
Tweet Send to a Friend
Fibrocell Science, Inc. (Nasdaq: FCSC) announced that the primary endpoints were not met in the Company’s Phase II clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
